Memantine in moderate-to-severe Alzheimer's disease

New England Journal of Medicine

Volumn 348, Issue 14, 2003, Pages 1333-1341

  Reisberg, Barry ^a   Doody, Rachelle ^b   Stöffler, Albrecht ^c   Schmitt, Frederick ^d   Ferris, Steven ^a   Möbius, Hans Jörg ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CAREGIVER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DISTRESS SYNDROME; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; NERVE DEGENERATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; BEHAVIOR; COGNITION; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; N-METHYLASPARTATE; SEVERITY OF ILLNESS INDEX;

EID: 0037417238     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa013128     Document Type: Article

References (27)

1. Khachaturian ZS. Plundered memories. Sciences 1997;37(4):20-5.
2. Reisberg B, Burns A, Broadty H, et al. Diagnosis of Alzheimer's disease: report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. Int Psychogeriatr 1997;9:Suppl 1:11-38.
3. Henderson AS, Jorm AF. Definition and epidemiology of dementia: a review. In: Maj M, Sartorius N, eds. Dementia. 2nd ed. Chichester, England: John Wiley, 2002:1-33.
4. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
5. Physicians' desk reference. 56th ed. Montvale, N.J.: Medical Economics, 2002: 1270-3, 1351-5, 1792-6, 2342-8, 2665-7.
6. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem 1984; 42:1-11.
7. Orrego F, Villanueva S. The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization. Neuroscience 1993;56:539-55.
8. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613-22.
9. Shimizu E, Tang YP, Rampon C, Tsien JZ. NMDA receptor-dependent synaptic reinforcement is a crucial process for memory consolidation. Science 2000;290;1170-4. [Erratum, Science 2001;291:1902.]
10. Ackerley S, Grierson AI, Brownlees J, et al. Glutamate slows axonal transport of neurofilaments in transfected neurons. J Cell Biol 2000;150:165-76.
11. Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders: focus on schizophrenia and Alzheimer's disease. Prog Brain Res 1998;116:421-37.
12. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G. Neuroprotective and symptomalogical action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res 2000;2:85-98.
13. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14:135-46.
14. McKhann G, Drachman D, Folstein M, Karzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
15. Folstein MF, Folsteln SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
16. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9.
17. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr 1992;4:Suppl 1:55-69.
18. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-8.
19. Reisberg B, Schneider L, Doody R, et al. Clinical global measures of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11:Suppl 3:8-18.
20. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:Suppl 2:S33-S39.
21. Galasko DR, Schmitt FA, Jin S, et al. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol Aging 2000;21: Suppl 1:S168. abstract.
22. Panisset M, Roudier M, Saxton J, Boller F. Severe Impairment Battery: a neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-5.
23. Schmitt FA, Ashford W, Ernesto C, et al. The Severe Impairment Battery: Concurrent validity and assessment of longitudinal change in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:Suppl 2:S51-S56.
24. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
25. Wimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. Health economics of dementia. Chichester, England: John Wiley, 1998:465-99.
26. Gillings D, Koch G. The application of the principle of intent-to-treat to the analysis of clinical trials. Drug Inf J 1991;25:411-24.
27. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20. [Erratum, Neurology 2001;57:2153.]